doxapram

Trade name: dopram

Small moleculeapproved

Approved

Jun 23, 1965

Doxapram is an analeptic agent (a stimulant of the central nervous system). The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in respiratory rate. A pressor response may result following doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved cardiac output rather than peripheral vasoconstriction. Following doxapram administration, an increased release of catecholamines has been noted. Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels. Used as temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. — NCATS

Clinical trial activity

8 trials · 17 clinical orgs · 5 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
2

Earliest trial started Nov 1, 2006 (NCT00389909)

Timeline

1960s

  1. Jun 23, 1965

    Hikma — Earliest FDA Approval

  2. Jun 23, 1965

    West-Ward Pharmaceutical — NDA Secondary Org

  3. Jun 23, 1965

    Hikma — NDA Secondary Org

  4. Jun 23, 1965

    Hikma — NDA Organization

  5. Jun 23, 1965

    Hikma — Marketing Organization

1990s

  1. Jan 30, 1992

    Watson Pharmaceuticals — Marketing Organization

2000s

  1. Jan 10, 2003

    Athenex, Inc. — Marketing Organization

  2. Jan 10, 2003

    Chartwell Pharmaceuticals — Marketing Organization

  3. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedJun 23, 1965

Chemistry & pharmacology

Loading structure…

SMILES

CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O
Mol. weight
432.99 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone
  • 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone
  • ahr-619
  • ahr-619
  • dopram
  • dopram
  • dopram
  • dopram
  • doxapram
  • doxapram
  • doxapram
  • doxapram
  • doxapram
  • doxapram
  • doxapram
  • doxapram
  • (+-)-doxapram
  • (+-)-doxapram
  • doxapram hcl
  • doxapram hcl
  • doxapram hcl
  • doxapram hydrochloride
  • doxapram hydrochloride
  • doxapram hydrochloride
  • doxapram hydrochloride
  • doxapram hydrochloride hydrate
  • doxapram hydrochloride hydrate
  • doxapram hydrochloride hydrate
  • doxapram hydrochloride hydrate
  • doxapram hydrochloride hydrate
  • doxapram hydrochloride hydrate
  • doxapramum
  • doxapramum
  • stimulexin
  • stimulexin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06585163Phase 1Sep 30, 2024National Institute on Drug Abuse (NIDA), Quivive Pharma, Inc., The Cleveland Clinic
NCT04430790Phase 3Jun 15, 2020Erasmus University Rotterdam, Katholieke Universiteit Leuven, Nederlands Neonataal Netwerk (N3), the Netherlands, University of Amsterdam
NCT03894189N/AMay 31, 2019Beni Suef University
NCT02171910Phase 4Oct 1, 2016University of Helsinki
NCT02820025N/AOct 1, 2015Ningxia Medical University
NCT01022151Phase 2Nov 1, 2007King Faisal University
NCT00477451Phase 2May 1, 2007Alexza Pharmaceuticals, Inc., Columbia University, Icahn School of Medicine at Mount Sinai, State University of New York, Brooklyn
NCT00389909Phase 4Nov 1, 2006Maternite Regionale Universitaire, University of Lorraine
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Alexza Pharmaceuticals, Inc.For profit1112007
Beni Suef UniversityAcademic/Hospital1112019
Columbia UniversityAcademic/Hospital1012007
Erasmus University RotterdamAcademic/Hospital1112020
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012007
Katholieke Universiteit LeuvenAcademic/Hospital1012020
King Faisal UniversityAcademic/Hospital1112007
Maternite Regionale UniversitaireAcademic/Hospital1112006
National Institute on Drug Abuse (NIDA)Government1012024
Nederlands Neonataal Netwerk (N3), the NetherlandsAcademic/Hospital1012020
Ningxia Medical UniversityAcademic/Hospital1112015
Quivive Pharma, Inc.For profit1112024
State University of New York, BrooklynAcademic/Hospital1012007
The Cleveland ClinicAcademic/Hospital1012024
University of AmsterdamAcademic/Hospital1012020
University of HelsinkiAcademic/Hospital1112016
University of LorraineAcademic/Hospital1012006
17 organizations
Page 1 / 1

Marketing (7)

OrganizationOrg typeRelationshipDate
Athenex, Inc.For profitMKTGJan 10, 2003
Chartwell PharmaceuticalsFor profitMKTGJan 10, 2003
HikmaFor profitNDA2Jun 23, 1965
HikmaFor profitNDAJun 23, 1965
HikmaFor profitMKTGJun 23, 1965
Watson PharmaceuticalsFor profitMKTGJan 30, 1992
West-Ward PharmaceuticalFor profitNDA2Jun 23, 1965